The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Updates from a study evaluating ASTX727 + venetoclax for patients with AML
Tareq Abuasab, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some results from a Phase II study evaluating ASTX727, an orally administered fixed dose combination of decitabine and cedazuridine, plus venetoclax for patients with acute myeloid leukemia (AML) (NCT04746235). Dr Abuasab first discusses the patient population enrolled in this study, and then gives an overview of the overall response rate (ORR) observed and the tolerability of this regimen. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
